IDEXX Laboratories, Inc. vs Vanguard International High Dividend Yield ETF — how do they compare? IDEXX Laboratories, Inc. trades at $546.1 (market cap $43.58B), while Vanguard International High Dividend Yield ETF trades at $102. The key difference: Vanguard International High Dividend Yield ETF is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals.
| IDXX | VYMI | |
|---|---|---|
Market Cap | $43.58B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $766.68 | $101.60 |
52-Week Low | $526.44 | $79.95 |
Enterprise Value | $44.48B | — |
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories trades at $552.46, down 2.64% today, with neutral technical signals but strong fundamental performance. The company maintains robust profitability with 24.63% net margins and has beaten earnings expectations for three consecutive quarters. Recent news highlights AI integration in medical devices and upcoming Q2 2026 results on August 4, 2026. The stock shows consistent revenue growth from $3.4B in 2022 to $4.3B in 2025.
Outlook remains positive given earnings momentum and analyst consensus, though elevated valuation ratios (P/E 41.49) pose risks. Key catalysts include Q2 earnings release and continued AI adoption in veterinary diagnostics. Primary risks involve competitive pressures and market volatility affecting premium valuations.
VYMI trades at $100.23, down 0.65% with a bullish technical signal from moving averages while oscillators remain neutral. The ETF offers international high dividend yield exposure with over 1,500 stocks and has delivered 10.8% annualized returns over 10 years. Recent institutional buying by D.A. Davidson & CO. increased their position by 265.6% during the latest quarter.
VYMI presents a compelling international diversification opportunity with strong dividend growth potential, though currency fluctuations and global economic conditions pose risks. The ETF's low 0.07% expense ratio and broad diversification across developed and emerging markets provide defensive characteristics in uncertain market environments.
Trailing returns across standard periods
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →VYMI is an index-based ETF that provides exposure to non-U.S. companies across developed and emerging markets that are characterized by high dividend yields. It tracks the FTSE All-World ex US High Dividend Yield Index, offering a diversified, low-cost way to capture international income while serving as a tactical hedge against U.S. market concentration.
Read more on VYMI →